布洛芬

常用名 布洛芬 英文名 Ibuprofen
CAS号 15687-27-1 分子量 206.281
密度 1.0±0.1 g/cm3 沸点 319.6±11.0 °C at 760 mmHg
分子式 C13H18O2 熔点 77-78 °C(lit.)
MSDS布洛芬的MSDS|SDS|pdf下载 中文版 美版 闪点 216.7±14.4 °C
符号 GHS07
GHS07
信号词 Warning

 布洛芬用途


具有抗炎、镇痛、解热作用。治疗风湿和类风湿关节炎的疗效稍逊于乙酰水杨酸和保泰松。适用于治疗风湿性关节炎、类风湿性关节炎、骨关节炎、强直性脊椎炎和神经炎等。该品在1985年美国药物销售额排列顺序中位列第十三。


 布洛芬物理化学性质

[ 密度 ]: 1.0±0.1 g/cm3
[ 沸点 ]: 319.6±11.0 °C at 760 mmHg
[ 熔点 ]: 77-78 °C(lit.)
[ 分子式 ]: C13H18O2
[ 分子量 ]: 206.281
[ 闪点 ]: 216.7±14.4 °C
[ 精确质量 ]: 206.130676
[ PSA ]: 37.30000
[ LogP ]: 3.72
[ 外观性状 ]: 无色,结晶固体
[ 蒸汽压 ]: 0.0±0.7 mmHg at 25°C
[ 折射率 ]: 1.519
[ 储存条件 ]:

常温密闭避光,通风干燥

[ 稳定性 ]:

常温常压下稳定

避免的物料: 氧化物
[ 水溶解性 ]: insoluble
[ 计算化学 ]:

1.疏水参数计算参考值(XlogP):无

2.氢键供体数量:1

3.氢键受体数量:2

4.可旋转化学键数量:4

5.互变异构体数量:无

6.拓扑分子极性表面积37.3

7.重原子数量:15

8.表面电荷:0

9.复杂度:203

10.同位素原子数量:0

11.确定原子立构中心数量:0

12.不确定原子立构中心数量:1

13.确定化学键立构中心数量:0

14.不确定化学键立构中心数量:0

15.共价键单元数量:1

[ 更多 ]:

1.性状:白色结晶性粉末。有异臭,无味。

2.密度(g/mL,25/4℃):未确定

3.相对蒸汽密度(g/mL,空气=1):未确定

4.熔点(ºC):77-78

5.沸点(ºC,常压):未确定

6.沸点(ºC,5.2kPa):未确定

7.折射率:未确定

8.闪点(ºC):未确定

9.比旋光度(º):未确定

10.自燃点或引燃温度(ºC):未确定

11.蒸气压(kPa,25ºC):未确定

12.饱和蒸气压(kPa,60ºC):未确定

13.燃烧热(KJ/mol):未确定

14.临界温度(ºC):未确定

15.临界压力(KPa):未确定

16.油水(辛醇/水)分配系数的对数值:未确定

17.爆炸上限(%,V/V):未确定

18.爆炸下限(%,V/V):未确定

19.溶解性:不溶于水

 布洛芬MSDS

2-(4-异丁苯基)丙酸 修改号码:5

模块1. 化学品
产品名称: 2-(4-Isobutylphenyl)propionic Acid
修改号码: 5

模块2. 危险性概述
GHS分类
 物理性危害未分类
 健康危害
急性毒性(经口) 第4级
皮肤腐蚀/刺激 第2级
严重损伤/刺激眼睛 2A类
 环境危害未分类
GHS标签元素
 图标或危害标志
 信号词警告
 危险描述吞咽有害。
造成皮肤刺激
造成严重眼刺激
 防范说明
[预防]使用本产品时切勿吃东西,喝水或吸烟。
处理后要彻底清洗双手。
穿戴防护手套/护目镜/防护面具。
[急救措施] 食入:若感不适,呼叫解毒中心/医生。漱口。
眼睛接触:用水小心清洗几分钟。如果方便,易操作,摘除隐形眼镜。继续冲洗。
眼睛接触:求医/就诊
皮肤接触:用大量肥皂和水轻轻洗。
若皮肤刺激:求医/就诊。
脱掉被污染的衣物,清洗后方可重新使用。
[废弃处置] 根据当地政府规定把物品/容器交与工业废弃处理机构。
2-(4-异丁苯基)丙酸 修改号码:5

模块3. 成分/组成信息
单一物质/混和物单一物质
化学名(中文名): 2-(4-异丁苯基)丙酸
百分比: >98.0%(GC)(T)
CAS编码: 15687-27-1
俗名: Ibuprofen , 4-Isobutyl-α-methylphenylacetic Acid
分子式: C13H18O2

模块4. 急救措施
吸入: 将受害者移到新鲜空气处,保持呼吸通畅,休息。若感不适请求医/就诊。
皮肤接触: 立即去除/脱掉所有被污染的衣物。用大量肥皂和水轻轻洗。
若皮肤刺激或发生皮疹:求医/就诊。
眼睛接触:用水小心清洗几分钟。如果方便,易操作,摘除隐形眼镜。继续清洗。
如果眼睛刺激:求医/就诊。
食入: 若感不适,呼叫解毒中心/医生。漱口。
危害迹象: 发烧, 肝炎, 月经周期异常, 复视, 过敏, 肿胀, 皮炎
紧急救助者的防护:救援者需要穿戴个人防护用品,比如橡胶手套和气密性护目镜。

模块5. 消防措施
合适的灭火剂:干粉,泡沫,雾状水,二氧化碳
特定方法:从上风处灭火,根据周围环境选择合适的灭火方法。
非相关人员应该撤离至安全地方。
周围一旦着火:如果安全,移去可移动容器。
消防员的特殊防护用具:灭火时,一定要穿戴个人防护用品。

模块6. 泄漏应急处理
个人防护措施,防护用具, 使用个人防护用品。远离溢出物/泄露处并处在上风处。
紧急措施:泄露区应该用安全带等圈起来,控制非相关人员进入。
环保措施:防止进入下水道。
控制和清洗的方法和材料:清扫收集粉尘,封入密闭容器。注意切勿分散。附着物或收集物应该立即根据合适的
法律法规处置。

模块7. 操作处置与储存
处理
技术措施:在通风良好处进行处理。穿戴合适的防护用具。防止粉尘扩散。处理后彻底清洗双手
和脸。
注意事项:如果粉尘或浮质产生,使用局部排气。
操作处置注意事项:避免接触皮肤、眼睛和衣物。
贮存
储存条件:保持容器密闭。存放于凉爽、阴暗处。
远离不相容的材料比如氧化剂存放。
包装材料:依据法律。

模块8. 接触控制和个体防护
工程控制:尽可能安装封闭体系或局部排风系统,操作人员切勿直接接触。同时安装淋浴器和洗
眼器。
个人防护用品
 呼吸系统防护:防尘面具。依据当地和政府法规。
 手部防护:防护手套。
 眼睛防护:安全防护镜。如果情况需要,佩戴面具。
2-(4-异丁苯基)丙酸 修改号码:5

模块8. 接触控制和个体防护
 皮肤和身体防护:防护服。如果情况需要,穿戴防护靴。

模块9. 理化特性
外形(20°C):固体
外观: 晶体-粉末
颜色:白色类白色
气味:特殊味
pH:无数据资料
熔点: 76°C
沸点/沸程 157 °C/0.5kPa
闪点:无资料
爆炸特性
 爆炸下限:无资料
 爆炸上限:无资料
蒸气压: 6.32x10-3Pa/25°C
密度:无资料
溶解度:
[水] 不溶于(21mg/L, 25°C)
[其他溶剂]
易溶于:酒精
溶于:许多有机溶剂
log水分配系数 = 3.97

模块10. 稳定性和反应性
化学稳定性:一般情况下稳定。
危险反应的可能性:未报道特殊反应性。
须避免接触的物质氧化剂
危险的分解产物: 一氧化碳, 二氧化碳

模块11. 毒理学信息
急性毒性: orl-chd LDLo:469 mg/kg
orl-man LDLo:171 mg/kg
orl-rat LD50:636 mg/kg
orl-wmn TDLo:8 mg/kg
对皮肤腐蚀或刺激: skn-hmn 2%/2D
对眼睛严重损害或刺激:无资料
生殖细胞变异原性: cyt-mus-orl 1470 mg/kg/7D
sce-mus-ipr 50 mg/kg
sce-mus-orl 270 mg/kg
致癌性:
IARC =无资料
NTP =无资料
生殖毒性: rec-rat TDLo:270 mg/kg(17-21D preg)
orl-rat TDLo:9750 mg/kg(65D male)
orl-wmn TDLo:8 mg/kg(1D pre)
orl-mus TDLo:1260 mg/kg(7-13D preg)
RTECS 号码: MU6640000

模块12. 生态学信息
生态毒性:
2-(4-异丁苯基)丙酸 修改号码:5

模块12. 生态学信息
鱼类:无资料
甲壳类:无资料
藻类:无资料
残留性 / 降解性:无资料
潜在生物累积 (BCF): 3
土壤中移动性
 log水分配系数: 3.97
1.5 x 10-2
 土壤吸收系数 (Koc):
 亨利定律 3400
constant(PaM3/mol):

模块13. 废弃处置
如果可能,回收处理。请咨询当地管理部门。建议在可燃溶剂中溶解混合,在装有后燃和洗涤装置的化学焚烧炉中
焚烧。废弃处置时请遵守国家、地区和当地的所有法规。

模块14. 运输信息
联合国分类:与联合国分类标准不一致
UN编号:未列明

模块15. 法规信息
《危险化学品安全管理条例》(2002年1月26日国务院发布,2011年2月16日修订): 针对危险化学品的安全使用、
生产、储存、运输、装卸等方面均作了相应的规定。


模块16 - 其他信息
N/A

 布洛芬毒性和生态

布洛芬生态学数据:

通常对水体是稍微有害的,不要将未稀释或大量产品接触地下水,水道或污水系统,未经政府许可勿将材料排入周围环境。

CHEMICAL IDENTIFICATION

RTECS NUMBER :
MU6640000
CHEMICAL NAME :
Hydratropic acid, p-isobutyl-
CAS REGISTRY NUMBER :
15687-27-1
LAST UPDATED :
199801
DATA ITEMS CITED :
47
MOLECULAR FORMULA :
C13-H18-O2
MOLECULAR WEIGHT :
206.31
WISWESSER LINE NOTATION :
QVY&R DIY

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
180 mg/kg/3W-I
TOXIC EFFECTS :
Liver - jaundice, cholestatic
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
800 mg/kg
TOXIC EFFECTS :
Behavioral - coma Behavioral - somnolence (general depressed activity) Nutritional and Gross Metabolic - metabolic acidosis
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
1028 mg/kg
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Nutritional and Gross Metabolic - changes in potassium Nutritional and Gross Metabolic - metabolic acidosis
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
8 mg/kg
TOXIC EFFECTS :
Behavioral - headache Nutritional and Gross Metabolic - body temperature increase
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
120 mg/kg/W-I
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - effect, not otherwise specified Skin and Appendages - dermatitis, other (after systemic exposure) Nutritional and Gross Metabolic - body temperature increase
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - child
DOSE/DURATION :
480 mg/kg/17D-I
TOXIC EFFECTS :
Liver - hepatitis (hepatocellular necrosis), diffuse Immunological Including Allergic - uncharacterized Nutritional and Gross Metabolic - body temperature increase
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
171 mg/kg
TOXIC EFFECTS :
Behavioral - general anesthetic Vascular - BP lowering not characterized in autonomic section
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - child
DOSE/DURATION :
469 mg/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
429 mg/kg
TOXIC EFFECTS :
Lungs, Thorax, or Respiration - respiratory obstruction Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Nutritional and Gross Metabolic - metabolic acidosis
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
132 mg/kg/6D-I
TOXIC EFFECTS :
Blood - thrombocytopenia
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
96 mg/kg/3D-I
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - diplopia
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
636 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
626 mg/kg
TOXIC EFFECTS :
Behavioral - analgesia Biochemical - Metabolism (Intermediary) - effect on inflammation or mediation of inflammation Nutritional and Gross Metabolic - body temperature decrease
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
740 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Rectal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
530 mg/kg
TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex) Behavioral - changes in motor activity (specific assay) Gastrointestinal - hypermotility, diarrhea
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
740 mg/kg
TOXIC EFFECTS :
Behavioral - analgesia
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
320 mg/kg
TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex) Gastrointestinal - ulceration or bleeding from stomach
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
395 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Rectal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
620 mg/kg
TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex) Behavioral - changes in motor activity (specific assay) Gastrointestinal - hypermotility, diarrhea
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
495 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - hamster
DOSE/DURATION :
1690 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - species unspecified
DOSE/DURATION :
1 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
12 gm/kg/30D-C
TOXIC EFFECTS :
Liver - changes in liver weight Endocrine - changes in thymus weight Blood - hemorrhage
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
32760 mg/kg/26W-I
TOXIC EFFECTS :
Gastrointestinal - ulceration or bleeding from large intestine Kidney, Ureter, Bladder - changes in bladder weight Blood - normocytic anemia
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
200 mg/kg/4D-I
TOXIC EFFECTS :
Gastrointestinal - ulceration or bleeding from stomach
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Rectal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
12 gm/kg/30D-C
TOXIC EFFECTS :
Gastrointestinal - other changes Blood - normocytic anemia Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1300 mg/kg/2W-I
TOXIC EFFECTS :
Liver - other changes Liver - changes in liver weight Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
480 mg/kg/30D-I
TOXIC EFFECTS :
Gastrointestinal - ulceration or bleeding from stomach
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
9 gm/kg/90D-I
TOXIC EFFECTS :
Liver - changes in liver weight Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
8 mg/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - menstrual cycle changes or disorders
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
840 mg/kg
SEX/DURATION :
female 8-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
10 mg/kg
SEX/DURATION :
female 21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - other effects to embryo
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
600 mg/kg
SEX/DURATION :
female 3-5 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intrauterine
DOSE :
2 mg/kg
SEX/DURATION :
female 4 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Rectal
DOSE :
270 mg/kg
SEX/DURATION :
female 17-21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition Reproductive - Effects on Newborn - live birth index (measured after birth)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Rectal
DOSE :
891 mg/kg
SEX/DURATION :
female 17-21 day(s) after conception lactating female 21 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Rectal
DOSE :
1 gm/kg
SEX/DURATION :
female 17-21 day(s) after conception lactating female 4 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Rectal
DOSE :
810 mg/kg
SEX/DURATION :
male 60 day(s) pre-mating female 2 week(s) pre-mating - 7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Rectal
DOSE :
8100 mg/kg
SEX/DURATION :
male 60 day(s) pre-mating female 2 week(s) pre-mating - 7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
420 mg/kg
SEX/DURATION :
female 7-13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1260 mg/kg
SEX/DURATION :
female 7-13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
Cytogenetic analysis
TYPE OF TEST :
Sister chromatid exchange

MUTATION DATA

TEST SYSTEM :
Rodent - mouse
DOSE/DURATION :
270 mg/kg
REFERENCE :
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 393,123,1997 *** REVIEWS *** TOXICOLOGY REVIEW JTCTDW Journal of Toxicology, Clinical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.19- 1982- Volume(issue)/page/year: 30,23,1992 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X4905 No. of Facilities: 82 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 2249 (estimated) No. of Female Employees: 1246 (estimated)

 布洛芬安全信息

[ 符号 ]: GHS07
GHS07
[ 信号词 ]: Warning
[ 危害声明 ]: H302
[ 警示性声明 ]: P301 + P312 + P330
[ 个人防护装备 ]: dust mask type N95 (US);Eyeshields;Gloves
[ 危害码 (欧洲) ]: Xn:Harmful
[ 风险声明 (欧洲) ]: R22;R51/53;R63
[ 安全声明 (欧洲) ]: S36-S61-S36/37
[ 危险品运输编码 ]: 2811
[ WGK德国 ]: 3
[ RTECS号 ]: MU6640000
[ 包装等级 ]: III
[ 危险类别 ]: 6.1(b)
[ 海关编码 ]: 2924299090

 布洛芬合成线路

~94%

文献:Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences; Huang, Hanmin; Xia, Chungu; Xie, Pan Patent: US2013/303798 A1, 2013 ; Location in patent: Paragraph 0018; 0104; 0105 ;

~98%

文献:Council of Scientific and Industrial Research Patent: US6660883 B1, 2003 ; Location in patent: Page column 41-42 ;

~10%

文献:Council of Scientific and Industrial Research Patent: US6660883 B1, 2003 ; Location in patent: Page column 52-54 ;

~96%

文献:Council of Scientific and Industrial Research Patent: US6660883 B1, 2003 ; Location in patent: Page column 50-51 ;

~92%

文献:Babu, B. Ramesh; Balasubramaniam, K. K. Organic Preparations and Procedures International, 1994 , vol. 26, # 1 p. 123 - 125

~83%

文献:Ube Industries, Ltd. Patent: US4922010 A1, 1990 ;

~89%

文献:Rivera, Isaac; Colberg, Juan C.; Soderquist, John A. Tetrahedron Letters, 1992 , vol. 33, # 46 p. 6919 - 6922

~82%

文献:Hiyama; Inoue; Saito Synthesis, 1986 , vol. NO. 8, p. 645 - 647

~89%

文献:Shionogi and Co., Ltd. Patent: US4223132 A1, 1980 ;

~52%

文献:FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION Patent: US2011/54208 A1, 2011 ; Location in patent: Page/Page column 7-8 ;

~56%

文献:Tetrahedron Letters, , vol. 32, # 15 p. 1769 - 1770

~94%

文献:Patil; Wadia Synthetic Communications, 2002 , vol. 32, # 18 p. 2821 - 2827

~80%

文献:Damodar; Krishna Mohan; Khaja Lateef; Jayarama Reddy Synthetic Communications, 2005 , vol. 35, # 9 p. 1143 - 1150

~55%

文献:Francalanci, F.; Foa, M. Journal of Organometallic Chemistry, 1982 , vol. 232, # 1 p. 59 - 70

~90%

文献:Aramini, Andrea; Sablone, Manolo R.; Bianchini, Gianluca; Amore, Alessia; Fani, Michela; Perrone, Plinio; Dolce, Alberto; Allegretti, Marcello Tetrahedron, 2009 , vol. 65, # 10 p. 2015 - 2021

~%

文献:Chemical Communications, , # 12 p. 1067 - 1068

~%

文献:US5191095 A1, ;

~%

文献:Wong, Brian; Linghu, Xin; Crawford, James J.; Drobnick, Joy; Lee, Wendy; Zhang, Haiming Tetrahedron, 2014 , vol. 70, # 7 p. 1508 - 1515

~%

文献:Chemical Communications, , # 12 p. 1067 - 1068

~%

文献:Chemical Communications, , # 12 p. 1067 - 1068

~%

文献:Chemical Communications, , # 14 p. 1239 - 1240

~87%

文献:Nisshin Flour Milling Co., Ltd. Patent: US3965161 A1, 1976 ;

~91%

文献:Rao, Gopal Krishna; Gowda, Narendra B.; Ramakrishna, Ramesha A. Synthetic Communications, 2012 , vol. 42, # 6 p. 893 - 904

~88%

文献:Tona, Merce; Sanchez-Baeza, Francisco; Messeguer, Angel Tetrahedron, 1994 , vol. 50, # 27 p. 8117 - 8126

~%

文献:Chemical and Pharmaceutical Bulletin, , vol. 31, # 9 p. 3139 - 3148

~%

文献:US4242519 A1, ;

~68%

文献:Fassina, Viviane; Ramminger, Carolina; Seferin, Marcus; Monteiro, Adriano L Tetrahedron, 2000 , vol. 56, # 38 p. 7403 - 7409

~%

文献:Journal of Organic Chemistry, , vol. 67, # 15 p. 5440 - 5443

~%

文献:US4542237 A1, ;

~%

文献:US4843172 A1, ;

~%

文献:US4008270 A1, ;

~75%

文献:Galletti, Paola; Pori, Matteo; Giacomini, Daria Synlett, 2010 , # 17 p. 2644 - 2648

~66%

文献:Uemura, Sakae; Ohe, Kouichi; Yamauchi, Takayoshi; Mizutaki, Shoichi; Tamaki, Kentaro Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1990 , # 4 p. 907 - 910

~81%

文献:Greenhalgh, Mark D.; Thomas, Stephen P. Journal of the American Chemical Society, 2012 , vol. 134, # 29 p. 11900 - 11903

~84%

文献:Kopinski, Richard P.; Pinhey, John T.; Rowe, Bruce A. Australian Journal of Chemistry, 1984 , vol. 37, # 6 p. 1245 - 1254

~88%

文献:Uemura, Sakae; Fukuzawa, Shin-ichi; Yamauchi, Takayoshi; Hattori, Kaneaki; Mizutaki, Shoichi; Tamaki, Kentaro Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1986 , p. 1983 - 1987

~%

详细
文献:Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, , vol. 40, # 12 p. 1166 - 1169

~98%

文献:Clericuzio, Marco; Degani, Iacopo; Dughera, Stefano; Fochi, Rita Synthesis, 2002 , # 7 p. 921 - 927

~93%

文献:Clericuzio, Marco; Degani, Iacopo; Dughera, Stefano; Fochi, Rita Synthesis, 2002 , # 7 p. 921 - 927

~92%

文献:Clericuzio, Marco; Degani, Iacopo; Dughera, Stefano; Fochi, Rita Synthesis, 2002 , # 7 p. 921 - 927

~90%

文献:Aramini, Andrea; Sablone, Manolo R.; Bianchini, Gianluca; Amore, Alessia; Fani, Michela; Perrone, Plinio; Dolce, Alberto; Allegretti, Marcello Tetrahedron, 2009 , vol. 65, # 10 p. 2015 - 2021

~94%

文献:Baiocchi, Leandro; Giannangeli, Marilena; Bonanomi, Michele; Picconi, Giuseppe; Ridolfi, Pietro Gazzetta Chimica Italiana, 1985 , vol. 115, # 4 p. 199 - 216

~71%

文献:Sonawane, Harikisan R.; Kulkarni, Dilip G.; Ayyangar, Nagaraj R. Tetrahedron Letters, 1990 , vol. 31, # 51 p. 7495 - 7496

~80%

文献:Kawai; Kato; Hamada; Shioiri Chemical and Pharmaceutical Bulletin, 1983 , vol. 31, # 9 p. 3139 - 3148

~%

文献:Journal of Organic Chemistry, , vol. 66, # 17 p. 5859 - 5865

~%

文献:Tetrahedron Letters, , vol. 33, # 46 p. 6919 - 6922

~%

文献:Tetrahedron Letters, , vol. 33, # 46 p. 6919 - 6922

~%

文献:Tetrahedron, , vol. 50, # 27 p. 8117 - 8126

~%

文献:Tetrahedron, , vol. 50, # 27 p. 8117 - 8126

~%

文献:Tetrahedron, , vol. 50, # 27 p. 8117 - 8126

~%

文献:Tetrahedron, , vol. 50, # 27 p. 8117 - 8126

~%

文献:Synthesis, , vol. NO. 8, p. 645 - 647

~%

文献:Synthesis, , vol. NO. 8, p. 645 - 647

~%

文献:Synthetic Communications, , vol. 32, # 18 p. 2821 - 2827

~%

文献:Synthetic Communications, , vol. 14, # 14 p. 1365 - 1372

~%

文献:Chemistry Letters, , p. 887 - 890

~%

文献:Chemical and Pharmaceutical Bulletin, , vol. 31, # 9 p. 3139 - 3148

~72%

文献:Tetrahedron, , vol. 50, # 4 p. 1243 - 1260

~%

文献:Journal of the American Chemical Society, , vol. 113, # 18 p. 7075 - 7076

~79%

文献:Hayashi, Sei-ichi; Nakai, Takeshi; Ishikawa, Nobuo Chemistry Letters, 1980 , p. 651 - 654

~97%

文献:Ebbers, Eelco J.; Ariaans, Gerry J. A.; Bruggink, Alle; Zwanenburg, Binne Tetrahedron Asymmetry, 1999 , vol. 10, # 19 p. 3701 - 3718

~%

文献:Journal of Medicinal Chemistry, , vol. 37, # 11 p. 1704 - 1711

~%

文献:Journal of Medicinal Chemistry, , vol. 37, # 11 p. 1704 - 1711

~%

文献:Australian Journal of Chemistry, , vol. 37, # 6 p. 1245 - 1254

~%

文献:Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), , p. 1433 - 1436

~%

文献:WO2010/51044 A1, ; Page/Page column 46; 47; 49 ; WO 2010/051044 A1

~%

文献:Journal of Organic Chemistry, , vol. 50, # 25 p. 5370 - 5372

~%

文献:Journal of Organic Chemistry, , vol. 50, # 25 p. 5370 - 5372

~%

文献:Tetrahedron Letters, , vol. 33, # 46 p. 6919 - 6922

~%

文献:Journal of Organic Chemistry, , vol. 47, # 24 p. 4692 - 4702

~%

文献:Journal of Organic Chemistry, , vol. 47, # 24 p. 4692 - 4702

~%

文献:Tetrahedron Letters, , vol. 25, # 4 p. 427 - 428

~%

文献:Tetrahedron Letters, , vol. 34, # 33 p. 5333 - 5336

~%

文献:Synthesis, , # 7 p. 921 - 927

~%

文献:Synthesis, , # 7 p. 921 - 927

~%

文献:Synthesis, , # 7 p. 921 - 927

~%

文献:Synthesis, , # 7 p. 921 - 927

~%

文献:Synthesis, , # 7 p. 921 - 927

~%

文献:Synthesis, , # 7 p. 921 - 927

~%

文献:Synthesis, , # 7 p. 921 - 927

~%

文献:Synthesis, , # 7 p. 921 - 927

~%

文献:Tetrahedron, , vol. 50, # 27 p. 8117 - 8126

~%

文献:Tetrahedron Letters, , vol. 27, # 34 p. 3995 - 3998

~%

文献:Chemische Berichte, , vol. 124, p. 1667 - 1672

~%

文献:Chemische Berichte, , vol. 124, p. 1667 - 1672

~86%

详细
文献:Journal of Organic Chemistry, , vol. 52, # 2 p. 287 - 290

~15%

文献:Synlett, , # 17 p. 2644 - 2648

~%

文献:Bulletin of the Chemical Society of Japan, , vol. 81, # 5 p. 617 - 622

~%

文献:Journal of Pharmacology and Experimental Therapeutics, , vol. 337, # 3 p. 876 - 886

~%

文献:Journal of the American Chemical Society, , vol. 134, # 29 p. 11900 - 11903

~%

文献:Chemistry Letters, , vol. 41, # 12 p. 1597 - 1599

~%

文献:US2013/303798 A1, ;

~%

文献:Tetrahedron, , vol. 70, # 7 p. 1508 - 1515

~%

文献:Tetrahedron, , vol. 70, # 7 p. 1508 - 1515

~%

文献:Journal of Organic Chemistry, , vol. 47, # 24 p. 4692 - 4702

~%

文献:European Journal of Medicinal Chemistry, , vol. 34, # 7-8 p. 551 - 562

~%

文献:European Journal of Medicinal Chemistry, , vol. 34, # 7-8 p. 551 - 562

~%

文献:Tetrahedron Letters, , vol. 32, # 28 p. 3369 - 3370

~%

文献:Synthesis, , # 5 p. 505 - 506

~%

文献:Tetrahedron Letters, , vol. 32, # 28 p. 3369 - 3370

~%

文献:Tetrahedron Letters, , vol. 32, # 28 p. 3369 - 3370

~%

文献:Tetrahedron Letters, , vol. 32, # 28 p. 3369 - 3370

~%

文献:Tetrahedron Letters, , vol. 32, # 28 p. 3369 - 3370

~%

文献:Tetrahedron, , vol. 51, # 46 p. 12645 - 12660

~%

文献:Chemistry Letters, , p. 887 - 890

~66%

文献:Reetz, Manfred T.; Carballeira, Jose Daniel; Peyralans, Jerome; Hoebenreich, Horst; Maichele, Andrea; Vogel, Andreas Chemistry - A European Journal, 2006 , vol. 12, # 23 p. 6031 - 6038

~%

文献:Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), , p. 1070 - 1071

~%

文献:Bioorganic and Medicinal Chemistry Letters, , vol. 17, # 5 p. 1447 - 1450

~%

文献:Pharmazie, , vol. 49, # 6 p. 422 - 424

~%

文献:Pharmazie, , vol. 49, # 6 p. 422 - 424

~%

文献:Pharmazie, , vol. 49, # 6 p. 422 - 424

~%

文献:Pharmazie, , vol. 49, # 6 p. 422 - 424

~%

文献:Pharmazie, , vol. 49, # 6 p. 422 - 424

~%

文献:Tetrahedron Letters, , vol. 35, # 38 p. 7107 - 7110

~%

文献:Pharmaceutical Research, , vol. 20, # 2 p. 205 - 211

~%

文献:Pharmaceutical Research, , vol. 20, # 2 p. 205 - 211

~%

文献:Pharmaceutical Research, , vol. 20, # 2 p. 205 - 211

~%

文献:Tetrahedron, , vol. 34, # 20 p. 3081 - 3088

~%

文献:Synthetic Communications, , vol. 6, p. 349 - 355

~%

文献:Journal of the Chemical Society, Chemical Communications, , # 11 p. 759 - 760

~%

文献:Arzneimittel-Forschung/Drug Research, , vol. 30, # 9 p. 1607 - 1609

 布洛芬制备

异丁基苯乙酮经缩合、水解、消除、氧化、中和而得。

 布洛芬海关

[ 海关编码 ]: 2916392000
[ 中文概述 ]: 2916392000 布洛芬。监管条件:无。增值税率:17.0%。退税率:9.0%。最低关税:6.5%。普通关税:30.0%
[申报要素 ]: 品名, 成分含量, 用途, 丙烯酸、丙烯酸盐或酯应报明包装
[ Summary ]: 2916392000 2-(4-isobutylphenyl)propanoic acid。Supervision conditions:None。VAT:17.0%。Tax rebate rate:9.0%。Lowest tariff:6.5%。General tariff:30.0%

 布洛芬文献403

更多文献
Environmental friendly method for urban wastewater monitoring of micropollutants defined in the Directive 2013/39/EU and Decision 2015/495/EU.

J. Chromatogr. A. 1418 , 140-9, (2015)

The fate and removal of organic micropollutants in the environment is a demanding issue evidenced by the recent European policy. This work presents an analytical method for the trace quantification of...

Validation of cyclooxygenase-2 as a direct anti-inflammatory target of 4-O-methylhonokiol in zymosan-induced animal models.

Arch. Pharm. Res. 38 , 813-25, (2015)

4-O-methylhonokiol (MH) is known to inhibit inflammation by partially understood mechanisms. Here, the anti-inflammatory mechanisms of MH were examined using enzymatic, cellular, and animal assays. In...

Probiotic properties of lactic acid bacteria isolated from water-buffalo mozzarella cheese.

Probiotics Antimicrob Proteins 6 , 141-56, (2014)

This study evaluated the probiotic properties (stability at different pH values and bile salt concentration, auto-aggregation and co-aggregation, survival in the presence of antibiotics and commercial...